Join the Cometriq group to help and get support from people like you.
Cometriq News
Cabozantinib Promising for Metastatic Pheochromocytomas, Paragangliomas
MONDAY, April 29, 2024 – For patients with metastatic pheochromocytomas and paragangliomas (MPPGs), an antiangiogenic multi-tyrosine kinase inhibitor, cabozantinib, is promising, according to a...
Cabozantinib Promising for Advanced Adrenocortical Carcinoma
FRIDAY, April 26, 2024 – For patients with advanced adrenocortical carcinoma, cabozantinib shows promising efficacy, according to a study published online April 9 in The Lancet Oncology. Matthew T....
Ask a question
To post your own question to this support group, sign in or create an account.